Keytruda Cements Cervical Cancer Leadership With First-Line Nod
Although the label’s PD-L1 expression requirement could limit the addressable market, there is also potential for future combination with Seagen’s recently approved Tivdak.
You may also be interested in...
Failure For AZ’s Imfinzi In CALLA Strengthens Keytruda’s Cervical Cancer Hold
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.
Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.